NCT07862764Not yet recruiting
A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections
Post Marketing Safety Study to Evaluate the Safety and Effectiveness of Epcoritamab in Korean Adult Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) represents approximately 50% of all newly diagnosed patients with non-Hodgkin lymphoma. This study will assess adverse events and change in disease activity in adult Korean participants with DLBCL under routine clinical practice. Epcoritamab is an approved drug for the treatment of DLBCL and FL. Approximately 175 adult participants who are prescribed epcoritamab by their doctors will be enrolled sites in Korea. Participants will receive epcoritamab as prescribed by their physician. Participants will be followed for up to 24 weeks. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 175 (estimated)
- First submitted
- 2 Oct 2026
- Start date
- 2 Oct 2026
- Primary completion date
- Nov 2029
- Lead sponsor
- AbbVie
- NCT number
- NCT07862764
What you commit to
- Study type: Observational
- Planned participants: 175
- From 2 Oct 2026 to the primary completion date, Nov 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Contraindication to epcoritamab as listed on the latest approved local label.
- Currently participating in another clinical research except observational study.
Who the study is looking for
- Participants who have agreed to receive epcoritamab treatment according to the latest approved local label or have already started epcoritamab treatment as per the approved label information at the time of the first administration of epcoritamab.
- Participants who voluntarily agree to participate in this study and sign informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.